Celcuity’s gedatolisib doubled progression-free survival versus standard of care in certain patients with advanced breast ...

A three-drug regimen incorporating AstraZeneca's immune checkpoint inhibitors Imfinzi and Imjudo has reduced the risk of ...

“Donald Trump endorsed Mike Mazzei in this race because their conservative policy goals are aligned,“ Speno said. “President ...

Adam Kittai, MD, breaks down the evolving landscape of CLL sequencing—from venetoclax retreatment to triplet regimens. As he ...

Adding a new once-daily pill to a combination of drugs already used on the NHS could help patients with a with an incurable blood cancer live longer without the disease getting worse, according to ...

CHICAGO -- Adding a novel cereblon E3 ligase modulation (CELMoD) drug to a standard multiple myeloma regimen significantly improved progression-free survival (PFS) in a vulnerable population of ...

From rookies like Fernando Mendoza to experienced former starters, here are the players one rep away from being QB1.

Patients battling an incurable blood cancer could live significantly longer without their disease progressing, thanks to a new once-daily pill that may soon be added to existing NHS treatments, ...

$1 million awarded through the SETI Institute’s STRIDE (Support Technology, Research, Innovation, Development, and Education) ...

East Greenwich's 12-11 win over Barrington was either the longest shortest game or the shortest longest game. Here's the wild ...

U.S. study supports findings from a global trial using an external control arm ...

In this global phase 3 trial, investigators assessed tafasitamab and lenalidomide plus R-CHOP versus standard-of-care R-CHOP for safety and efficacy in patients with previously untreated DLBCL.